Papazol-Darnitsa 2p x 10 tablets — Made in Ukraine — Free Delivery

Pharmacological properties

Papazol-Darnitsa is a combined preparation, which contains the alkaloid papaverine and an imidazole derivative - bendazole.

Papaverine is a myotropic antispasmodic agent. It is an inhibitor of the enzyme PED, which causes intracellular accumulation of cyclic 3 ', 5'-adenosine monophosphate (cAMP). The accumulation of cAMP leads to impaired contractility of smooth muscles and their relaxation in spastic conditions. Reduces tone, reduces the contractile activity of smooth muscles and therefore has a vasodilator and antispasmodic effect. The effect of papaverine on the central nervous system is weak, only in higher doses it exhibits some sedative effect.

Bendazole is a myotropic antispasmodic agent. Directly affects the state of the smooth muscles of the vascular wall and internal organs due to the effect on imidazole receptors. Reduces blood pressure, the content of free calcium in smooth muscles, eliminates spasm of smooth muscles of the abdominal organs, stimulates the functions of the spinal cord. Increases the ability of tissues to withstand hypoxia, increases the synthesis of nucleic acids and protein.

Indications

Spasms of smooth muscles of internal organs (pylorospasm, spastic colitis, cholecystitis, gastric ulcer and duodenal ulcer, intestinal colic, renal colic, urinary tract spasms);

• transient spasm of cerebral vessels;
• moderately pronounced spasm of peripheral vessels;
• an additional agent in the complex therapy of hypertension.

Application

Assign to adults by mouth 2 hours before or after meals, 1 tablet 2-3 times a day. the maximum single dose is 1 tablet, the maximum daily dose is 4 tablets.

The duration of treatment is determined by the doctor depending on the nature and course of the disease, the effectiveness of therapy.

Contraindications

Hypersensitivity to the active substance or other components of the preparation; violation of av conductivity; severe heart failure; arterial hypotension; diseases accompanied by a decrease in muscle tone; convulsive syndrome, broncho-obstructive syndrome, bleeding ulcer of the stomach and duodenum; hypotonic colitis; habitual constipation; traumatic brain injury; severe hepatic and renal impairment; chronic nephritis with edema and impaired nitrogen excretory function of the kidneys; diabetes; hypothyroidism; adrenal insufficiency, prostatic hypertrophy, glaucoma.

In the case of rare hereditary conditions, due to which incompatibility with the auxiliary substance of the preparation is possible (see SPECIAL INSTRUCTIONS), taking the preparation is contraindicated.

Side effects

When using the preparation in some patients, there may be side reactions characteristic of papaverine and bendazole preparations.

From the respiratory system, chest and mediastinal organs: dry cough, rhinorrhea, shortness of breath.

From the gastrointestinal tract: nausea, constipation, discomfort in the stomach.

From the liver and biliary tract: increased activity of hepatic transaminases, jaundice.

From the nervous system: headache, drowsiness, weakness, dizziness.

From the side of the cardiovascular system: AV blockade, arrhythmias, decreased myocardial contractility, arterial hypotension, orthostatic hypotension, palpitations, pain in the heart, hot flashes, ventricular premature beats, tachycardia; with prolonged use - deterioration of ECG indicators due to a decrease in cardiac output.

On the part of the blood and lymphatic system: eosinophilia.

From the immune system: hypersensitivity reactions, including rash, itching, urticaria, Quincke's edema.

General disorders: increased sweating, hyperemia, a feeling of heat.

special instructions

Prescribe the preparation with caution and in doses below average therapeutic, in severe heart disease, supraventricular tachycardia, respiratory depression, decreased intestinal motility, shock, debilitated patients and the elderly.

It is not recommended to use the preparation  for long-term treatment of hypertension, especially in elderly patients.

When taking the preparation, orthostatic hypotension may develop.

If symptoms of liver dysfunction appear, in particular, gastrointestinal disturbances, jaundice, eosinophilia and an increase in the level of liver enzymes, it is necessary to stop taking the preparation.

You should inform your doctor about the following symptoms: hot flashes, increased sweating, headache, fatigue, jaundice, skin rashes, nausea, stomach discomfort, constipation.

Smoking reduces the effectiveness of the preparation.

While taking the preparation, you should stop using alcohol and preparations that suppress the central nervous system.

The preparation contains lactose, therefore, patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not take the preparation.

Use during pregnancy and lactation. The preparation is contraindicated during pregnancy or lactation.

Children. Do not use this medicine in children.

The ability to influence the rate of reactions when driving vehicles or other mechanisms. During preparation treatment, you should refrain from driving vehicles or working with other complex mechanisms.

Interactions

With the simultaneous use of Papazol with other preparations, the following types of interactions are possible:

• with antihypertensive preparations of different groups, tricyclic antidepressants, saluretics, procainamide, reserpine, quinidine, phentolamine - increased hypotensive effect; with prolonged use with β-adrenergic receptor blockers, the preparation prevents an increase in the total peripheral resistance caused by β-adrenergic blockers;
• with anticholinergics - an increase in the anticholinergic effect;
• with barbiturates - mutual enhancement of effects;
• with levodopa, methyldopa - weakening the effects of these preparations;
• with preparations  that suppress the central nervous system, - an increase in the toxicity of these preparations, such a combination is not recommended;
• with cardiac glycosides - a pronounced increase in the contractile function of the myocardium as a result of a decrease in the total peripheral vascular resistance;
• with adsorbents, astringents and coating agents - reducing the absorption of the preparation from the gastrointestinal tract.

The effectiveness of the preparation is reduced by smoking.

Overdose

Poisoning symptoms are a combination of an overdose of papaverine and bendazole.

Symptoms of bendazole poisoning: arterial hypotension, arrhythmia, increased sweating, fever, dizziness, nausea, headache, weakness, decreased tissue perfusion.

Symptoms of papaverine poisoning: anxiety, lethargy, drowsiness, weakness, headache, increased sweating, blurred vision, diplopia, shortness of breath, ataxia, nystagmus, CNS depression, sinus tachycardia, partial or complete AV block, arterial hypotension, collapse, coma cyanosis, metabolic acidosis, hyperventilation, hyperglycemia, hyperkalemia, nausea, vomiting, constipation, gastrointestinal disorders, skin rashes.

Treatment: preparation withdrawal, gastric lavage to clean wash water, saline laxative and activated charcoal. Symptomatic treatment. There is no specific antidote.

Storage conditions

Packaging at a temperature not exceeding 25 ° C.